Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3338-3344

  Belinsky, Steven A ^a   Liechty, Kieu C ^a   Gentry, Frederick D ^a   Wolf, Holly J ^b   Rogers, Justin ^b   Vu, Kieu ^b   Haney, Jerry ^b   Kennedy, Tim C ^b   Hirsch, Fred R ^b   Miller, York ^b   Franklin, Wilbur A ^b   Herman, James G ^c   Baylin, Stephen B ^c   Bunn, Paul A ^b   Byers, Tim ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MARKER GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SPUTUM CYTODIAGNOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 33645521023     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3408     Document Type: Article

References (47)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-66.
3. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer using presentation, histopathology and oncogene expression. Cancer Res 1995;55:51-6.
4. Read RC, Schaefer R, North N, Walls R. Diameter, cell type, and survival in stage I primary non-small cell lung cancer. Arch Surg 1988;123:446-9.
5. Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg 2003;76:1001-7.
6. Socinski MA. Adjuvant therapy of resected non-small cell lung cancer. Clin Lung Cancer 2004;63:162-9.
7. Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci 2001;952:124-34.
8. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003;1210:987-93.
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;36:415-28.
10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;34921:2042-54.
11. Herman JG, Graff J, Myohannen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;9318:9821-6.
12. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;6021:5954-8.
13. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;1818:3221-9.
14. INK4a alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004;441:23-32.
15. Zochbauer-Muller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003;1074:612-6.
16. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;2219:147-50.
17. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;628:2370-7.
18. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;5:963-8.
19. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;9520:11891-6.
20. Belinsky SA. Gene promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;49:707-17.
21. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;9314:1054-61.
22. Kennedy TC, Proudfoot SP, Piantadosi S, et al. Efficacy of two sputum collection techniques in patients with air flow obstruction. Acta Cytol 1999;434:630-6.
23. Saccomanno G. Diagnostic pulmonary cytology. American Society of Clinical Pathologists. Chicago (IL); 1978.
24. Petty TL, Tockman MS, Palcic B. Diagnosis of roentgenographically occult lung cancer by sputum cytology. Clin Chest Med 2002;231:59-64.
25. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of the transcription factor genes PAX5 α and β in human cancers. Cancer Res 2003;6315:4620-5.
26. 6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 2003;6316:4842-8.
27. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;253:315-9.
28. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 2001;2014:1765-70.
29. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-C cadherin) gene in breast and lung carcinomas. Cancer Res 2001;6111:4556-60.
30. Guo M, Akiyama Y, House MG, et al. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 2004;1023:7917-24.
31. Sathyanarayana UG, Toyooka S, Padar A, et al. Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 2003;97:2665-72.
32. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;812:3669-75.
33. Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 2005;1143:400-5.
34. Xu ZP, Dutra A, Stellrecht CM, Wu C, Piatigorsky J, Saunders, GF. Functional and structural characterization of the human gene BHLHB5, encoding a basic helix-loop-helix transcription factor. Genomics 2002;803:311-8.
35. Peyton M, Stellrecht CM, Naya FJ, Huang HP, Samora PJ, Tsai MJ. BETA3, a novel helix-loop-helix protein, can act as a negative regulator of BETA2 and MyoD-responsive genes. Mol Cell Biol 1996;162:626-33.
36. INK4a in primary rat lung tumors. Mol Cell Biol 1997;173:1366-74.
37. Pulling LC, Vuillemenot BR, Hutt JA, Devereux TR, Belinsky SA. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res 2004;6411:3844-8.
38. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;1118:6505-11.
39. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995;375:503-6.
40. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;126:2662-72.
41. 2+/ calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 1997;165:998-1008.
42. Cohen O, Inbal B, Kissil JL, et al. DAP-kinase participates in TNF-α and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999;1461:141-8.
43. Khokhlatchev A, Rabizadeh S, Xavier R, et al. Identification of a novel ras-regulated proapoptotic pathway. Curr Biol 2002;124:253-65.
44. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;609:2368-71.
45. Eckfeld K, Hesson L, Vos MD, Blieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 2004;6423:8688-93.
46. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005;2424:3987-94.
47. Yano M, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;1131:59-66.